Drug Approval | March 27, 2023
Briefs: Morepen Laboratories and Zydus Lifesciences
The company is addressing these observations
The company is addressing these observations
The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin’s marketed products worldwide
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking
Man Industries (India) Limited has received a new export order of approximately Rs. 1,300 crores.
KRIVIDA TRIVUS detects the specific virus causing a respiratory infection.
Lupin Bioresearch Centre conducts BA/BE, PK/PD, In-vitro BE and biosimilar studies.
The inspection concluded with no observations
Jan Aushadhi highlights achievements of women of the country at 34 locations by felicitating all women stakeholders under the scheme
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
Subscribe To Our Newsletter & Stay Updated
